Galera Therapeutics completes merger with Obsidian; becomes subsidiary of Obsidian Therapeutics

Galera Therapeutics, Inc.

Galera shareholders receive 0.7019 shares of Parent common stock per share; Legacy Obsidian shareholders receive 0.1383 shares per share.
Post-merger ownership: Legacy Obsidian ~51.6%, PIPE investors ~47.2%, Galera ~1.2% on fully diluted basis.
Galera shareholders receive CVRs: 80% of net proceeds from Legacy Product (tilarganine) over 5 years, 95% from Supportive-Care divestiture over 10 years.
Galera common stock to be delisted from OTCQB; company to file Form 15 to terminate SEC registration.
All prior directors resigned; new officers appointed (Madan Jagasia, Julie Feder, Parameswaran Hari, Dana Alexander).

item 1.01 item 2.01 item 3.01 item 3.03 item 5.01 item 5.02 item 5.03 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.